Literature DB >> 3182866

Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c.

E F Johnson1, G E Schwab, L E Vickery.   

Abstract

The binding of the amino steroid, 22-amino-23,24-bisnor-5-cholen-3 beta-ol (22-ABC), to rabbit liver cytochrome P-450 3c was studied using purified P-450 3c and liver microsomes prepared from rifampicin-treated B/J rabbits. 22-ABC binds to purified cytochrome P-450 3c producing a type II spectral change reflecting the coordination of the amine with the heme iron of the protein. In the absence of allosteric effectors, the binding is characterized by a Ks of 5 microM. In the presence of alpha-naphthoflavone or progesterone, the Ks decreases to 0.8 microM, indicating that these two compounds serve as positive effectors of the binding of 22-ABC to cytochrome P-450 3c. The antibiotic rifampicin induces cytochrome P-450 3c in rabbit liver microsomes, and the benzo(a)pyrene hydroxylase, estradiol 2-hydroxylase, and progesterone 6 beta-hydroxylase activities of these microsomes are stimulated by alpha-naphthoflavone. Moreover, the progesterone 6 beta-hydroxylase activity catalyzed by these microsomes exhibits a dependence on substrate concentration that is consistent with activation of the enzyme by the substrate, progesterone. The magnitude of the type II spectral change elicited by 22-ABC for microsomes prepared from rifampicin-treated B/J rabbits is greater than that observed for microsomes from untreated rabbits. For microsomes from rifampicin-treated rabbits, the apparent binding constant for 22-ABC was decreased 5-fold in the presence of alpha-naphthoflavone. We propose that the effects of alpha-naphthoflavone and progesterone on the binding of 22-ABC to cytochrome P-450 3c mimic the effects of the two positive effectors on the metabolism of substrates by increasing the affinity of the enzyme for substrate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182866

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Cytochrome P450(58 kDa): a possible universal hexameric structure of cytochromes P450 in membranes of hepatocytes.

Authors:  K N Myasoedova; V Ya Stel'mashchuk
Journal:  Dokl Biochem Biophys       Date:  2003 Nov-Dec       Impact factor: 0.788

2.  The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4.

Authors:  Chi-Chi Peng; Josh T Pearson; Dan A Rock; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Arch Biochem Biophys       Date:  2010-03-25       Impact factor: 4.013

Review 3.  Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?

Authors:  Dmitri R Davydov; James R Halpert
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

4.  Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.

Authors:  Alison Edelman; Myrna Munar; Miriam R Elman; Dennis Koop; Ganesh Cherala
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 5.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

6.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics.

Authors:  G R Harlow; J R Halpert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 7.  Cooperative properties of cytochromes P450.

Authors:  Ilia G Denisov; Daniel J Frank; Stephen G Sligar
Journal:  Pharmacol Ther       Date:  2009-06-23       Impact factor: 12.310

8.  Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity.

Authors:  J Cupp-Vickery; R Anderson; Z Hatziris
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.